在良性淋巴管内皮瘤中调查mTOR信号通路和西罗的反应
Xin Wen1, Daopei Zou1,2, Fazhan Ban1
1Department of Dermatology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
The Journal of dermatological treatment
|June 16, 2025
概括
良性淋巴血管内皮瘤涉及mTOR通路的激活. mTOR抑制剂西罗利木斯在治疗这些罕见的淋巴瘤方面显示出有希望的疗效和安全性,为治疗提供了一个新的治疗途径.
科学领域:
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
- 血管生物学 血管生物学
背景情况:
- 良性淋巴管内皮瘤是一种罕见的淋巴血管瘤,其病原性不明.
- 对于这种情况,有效的治疗选择有限.
研究的目的:
- 在良性淋巴管内皮瘤中研究mTOR信号通路的过度激活.
- 评估用于治疗的mTOR抑制剂西罗的临床疗效和安全性.
主要方法:
- 免疫组织化学染色以评估瘤样本中的mTOR通路激活.
- 临床监测三名接受口服西罗素治疗的患者.
主要成果:
- 在分析的7名患者中有7名观察到mTOR途径分子的过度表达.
- 所有三名接受治疗的患者都显示,皮肤病变在西洛斯的治疗中显著回归.
- 在西洛斯治疗期间没有报告任何显著的不良反应.
结论:
- mTOR通路的激活与良性淋巴管内皮质瘤的发病有关.
- 西洛利斯显示出有前途的治疗疗效和良性淋巴管内皮瘤的有利安全概况.
相关概念视频
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
01:22PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K